CLGN (collplant.com) חוב לטווח קצר להון

CollPlant Biotechnologies (CLGN) is developing a unique system for synthesizing human protein from flora, securing privileged contracts with leading aesthetic surgeons. The business relies on the creation of rhCollagen bio-inks for the B2B tissue 3D printing segment, which ensures high technological protection. The asset's market value dynamics, reaching 0.31, illustrate the trajectory of a biotech leader combining natural resources and innovation for organ restoration and wound healing.

Assessing the financial stability of CollPlant Biotechnologies (CLGN) requires an analysis of liquidity amid a moderate dependence on external research partners. This indicator measures the ratio of short-term liabilities to equity, while the share of short-term loans in the company's capital determines the speed of balance sheet adaptation to crises and the degree of asset loss risk during a sharp deterioration in market conditions.